July 23 (Reuters) - Abionyx Pharma SA ABNX.PA :
* GROSS CASH POSITION FOR FIRST SEMESTER OF 2020
* CASH AND CASH EQUIVALENTS AMOUNTED TO EUR 8.8 MILLION AT
JUNE
30TH, 2020
* COMPANY DID NOT GENERATE ANY REVENUE IN FIRST SEMESTER OF
2020
* GIVEN COVID-19 IMPACT ON HEALTHCARE SYSTEMS, COMPANY IS
STILL
AWAITING CLINICAL DATA THAT MAY INFLUENCE DETERMINATION OF NEW
STRATEGIC PLAN
Source text for Eikon: ID:nNDL4MNDT9
Further company coverage: ABNX.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))